Showing 981-990 of 20379 results for "".
Real-World Impact of Evolocumab on MACE Reduction in ASCVD
https://reachmd.com/clinical-practice/cardiology/real-world-impact-of-evolocumab-on-mace-reduction-in-ascvd/39991/Review real-world data on evolocumab and its association with reduced MACE in patients with established atherosclerotic cardiovascular disease.Treatment Patterns and MRA Use in Patients with HFmrEF/HFpEF: Insights From FRAME-HF and IRIS HF
https://reachmd.com/clinical-practice/cardiology/heart-failure-treatment-trends-insights-from-frame-hf-and-iris-hf/57080/Review ESC Heart Failure 2026 data on treatment patterns and MRA use in HF across the FRAME-HF and IRIS-HF cohorts.Finerenone in HFpEF: Key Insights From ESC HF
https://reachmd.com/clinical-practice/cardiology/finerenone-in-ckm-disease-and-hfpef-key-takeaways-from-esc-hf/49255/Review analyses from ESC Heart Failure 2026 examining finerenone in CKM disease and HFpEF, including outcomes in undiagnosed CKD.When Topicals Fail: The New IPC Consensus Every Clinician Should Know
https://reachmd.com/programs/cme/when-topicals-fail-the-new-ipc-consensus-every-clinician-should-know/39967/Review IPC’s 2025 consensus guidance on reclassifying psoriasis severity and redefining failure of topical therapies.RSV in Infants and Young Children: Are You Taking It Seriously Enough?
https://reachmd.com/programs/cme/RSV-in-Infants-and-Young-Children-Are-You-Taking-It-Seriously-Enough/39306/Explore RSV prevention strategies in infants, including maternal immunization and monoclonal antibodies, aligned with current AAP guidelines.From Pixels to Practice: Advancing HCM Care With Multimodality Imaging
https://reachmd.com/programs/cme/from-pixels-to-practice-advancing-hcm-care-with-multimodality-imaging/39877/Explore how multimodality imaging advances diagnosis, treatment selection, and monitoring in hypertrophic cardiomyopathy care.New Insights in the Management of HCM: Exploring the Clinical Spectrum
https://reachmd.com/programs/cme/new-insights-in-the-management-of-hcm-exploring-the-clinical-spectrum/33026/Explore personalized strategies in obstructive HCM, from diagnosis to treatment evolution, including real-world insights into cardiac myosin inhibitor use.Crossing Boundaries: CETP Inhibitors and the Next Frontier in Lipid Control
https://reachmd.com/programs/cme/crossing-boundaries-cetp-inhibitors-and-the-next-frontier-in-lipid-control/33025/Exploring CETP inhibition as the next breakthrough in lipid lowering, cardiologists highlight mechanisms, trials, and its role as a future CV therapy.CETP Inhibition With Obicetrapib: Implications for Cardiovascular Event Prevention
https://reachmd.com/clinical-practice/cardiology/cetp-inhibition-with-obicetrapib-implications-for-cardiovascular-event-prevention/37124/CETP Inhibition with Obicetrapib: Implications for Cardiovascular Event PreventionCETP Inhibition and Obicetrapib: A New Era in Lipid Management
https://reachmd.com/clinical-practice/cardiology/cetp-inhibition-and-obicetrapib-a-new-era-in-lipid-management/37123/CETP Inhibition and Obicetrapib: A New Era in Lipid Management